Abstract 2611: Evaluation of ANG/TIE/hypoxia pathway genes and signatures as predictors of response to trebananib (AMG 386) in the neoadjuvant I-SPY 2 TRIAL for Stage II-III high-risk breast cancer
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-2611
Abstract: Background: The angiogenesis (ANG1/2) inhibitor trebananib (TR) was one of the experimental agents evaluated in I-SPY 2. In I-SPY 2, all patients received at least standard chemotherapy (paclitaxel followed by doxorubicin/cyclophosphamide: T->AC). HER2- patients were… read more here.
Keywords: arm; ang tie; response; genes signatures ... See more keywords